Table 1 Baseline characteristics of the study population (N = 216)
Sociodemographics and other risk factors | Total n (%) | Sex | |
|---|---|---|---|
Female 49 (23%) | Male 167 (77%) | ||
Age (mean ± SD) | 65.7 ± 11.2 | 65.0 ± 10.6 | 65.9 ± 11.4 |
Age, years | |||
< 34 | 4 (1.9) | 0 | 4 (2.4) |
35–44 | 8 (3.7) | 2 (4.1) | 6 (3.6) |
45–54 | 16 (7.4) | 7 (14.3) | 9 (5.4) |
55–64 | 62 (28.7) | 14 (28.6) | 48 (28.7) |
≥ 65 | 126 (58.3) | 26 (53.1) | 100 (59.9) |
Smoking | |||
Yes | 58 (26.9) | 1 (2.0) | 57 (34.1) |
Hypertension | |||
Yes | 205 (94.9) | 47 (95.9) | 158 (94.6) |
Hypertension grade | |||
Normal | 123 (56.9) | 26 (53.1) | 97 (58.1) |
Grade 1 | 68 (31.5) | 16 (32.7) | 52 (31.1) |
Grade 2 | 18 (8.3) | 3 (6.1) | 15 (9.0) |
Grade 3 | 7 (3.2) | 4 (8.2) | 3 (1.8) |
Diabetes mellitus | |||
Yes | 135 (62.5) | 28 (57.1) | 107 (64.1) |
Total cholesterol, mmol/L | |||
> 5.17 | 44 (20.4) | 13 (26.5) | 31 (18.6) |
LDL cholesterol, mmol/L | |||
≥ 2.6 | 109 (50.5) | 28 (57.1) | 81 (48.5) |
BMI, mean ± SD | 27.0 ± 5.1 | 29.1 ± 5.3 | 26.4 ± 4.9 |
BMI, kg/m2 | |||
≤ 24.99 | 74 (34.3) | 10 (20.4) | 64 (38.3) |
25–29.99 | 83 (38.4) | 19 (38.8) | 64 (38.3) |
30–34.99 | 43 (19.9) | 11 (22.4) | 32 (19.2) |
> 35 | 16 (7.4) | 9 (18.4) | 7 (4.2) |
Anti-platelet medication | |||
Yes | 113 (52.3) | 27 (55.1) | 86 (51.5) |
Statins | |||
Yes | 184 (85.2) | 40 (81.6) | 144 (86.2) |
Persons-years of follow-up | 1184.0 | 250.4 | 933.6 |
Recurrent CVD events | 109 | 30 | 79 |